You are here:

pramipexole (Mirapexin)


Following an abbreviated submission

pramipexole dihydrochloride monohydrate prolonged release tablets 0.375mg, 0.75mg, 1.5mg, 3.0mg, 4.5mg (equivalent to 0.26mg, 0.52mg, 1.05mg, 2.1mg, 3.15mg pramipexole) (Mirapexin) are accepted for use in NHS Scotland for: treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or “on off” fluctuations).

In patients for whom the use of pramipexole is appropriate, the prolonged-release formulation can provide the same daily dose as existing immediate release formulations, with the benefit of once-daily rather than thrice-daily dosing, at an equivalent cost.

Drug Details

Drug Name: pramipexole (Mirapexin)
SMC Drug ID: 580/09
Manufacturer: Boehringer Ingelheim Ltd
Indication: Parkinson’s disease
BNF Category:
Sub Category: 4.9 Drugs used in Parkinsonism and related disorders
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 9 November 2009